Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT04706234
Recruiting Observational

Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases

NCT04706234 · tracked via the Priya Life Science Spain tracker
Sponsor
Kliniken Beelitz GmbH
Phase
Observational
Started
2017-09-01
Last updated
2025-04-09

Condition(s) studied

Multiple System AtrophyParkinson DiseaseProgressive Supranuclear PalsyMotor Neuron DiseaseNeurodegenerative Diseases

Study summary

This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders. The results of a fiberoptic / flexible endoscopic evaluation of swallowing (FEES) while performing a structured task protocol will be recorded. If available, laryngeal electromyography (EMG) results will also be recorded. In addition to the examination results, demographic and disease-specific data are collected, and two questionnaires, the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) and the swallowing specific Quality Of Life Questionnaire (SWALQOL), are administered.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * diagnosis of probable or possible multiple system atrophy according to current consensus criteria (Gilman et al. 2008) or * diagnosis of probable or possible PSP according to the the Movement Disorders Society (MDS) diagnostic criteria (Höglinger et al. 2017) or * diagnosis of Parkinson's disease according to the MDS diagnostic criteria (Postuma et al 2015) * Hoehn and Yahr Stage within the range of I-V or * diagnosis of motor neurone disease or * diagnosis of a neurodegenerative disease other than specified above AND underwent laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019). Exclusion Criteria: \- Patients who do not sign the consent form

Primary outcome measure(s)

  • laryngeal movement disorders — 1 day
    occurrence of vocal fold motion impairment, paradoxical vocal fold motion, vocal fold fixation or involuntary irregular arytenoid cartilages movements when assessed with the task-protocol
  • dysphagia — 1 day
    occurrence of dysphagic symptoms when assessed with the task-protocol

Trial sites (16)

FacilityCityRegionStatus
Department of Neurology and Department of ENT, Medical University Innsbruck Innsbruck Tyrol Recruiting
Department of Neurology, Medical University of Ulm Ulm Baden-Wurttemberg Recruiting
Movement Disorders Hospital - Kliniken Beelitz Beelitz-Heilstätten Brandenburg Recruiting
Department of Neurology, Medical School Hannover Hanover Lower Saxony Recruiting
Department of Neurology, University Hospital Münster Münster North Rhine-Westphalia Recruiting
Department of Neurology, University Hospital Carl Gustav Carus Dresden Saxony Recruiting
Department of Neueology Asklepios Klinik Stadtroda Stadtroda Thuringia Recruiting
Asklepios Fachklinikum Stadtroda Stadtroda Thuringia Recruiting
Asklepios Klinik Barmbek Hamburg Germany Recruiting
Department of Neurology Asklepios Klinik Barmbek Hamburg Germany Recruiting
Department of Neurology, Movement Disorders Unit, Medical Center Tel Aviv Tel Aviv Israel Recruiting
IRCCS Istituto delle Scienze Neurologiche, Azienda USL di Bologna Bologna Italy Recruiting
Department of Neurology, Gifu University Graduate School of Medicine Gifu Japan Recruiting
Department of Neurology, Medical University Warsaw Warsaw Poland Recruiting
Department of Neurology SNUCM Seoul South Korea Recruiting
Unidad de Parkinson y Trastornos del Movimiento Instituto Clínic de Neurociencias, Hospital Clinic de Barcelona Barcelona Catalonia Recruiting

Other trials for the same condition

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD) Active, not recruiting
Effectiveness of Virtual Reality in Parkinson's Disease: Effects on Balance, Fall Risk, and Exercise Capacity. Starting soon
Deep Brain Stimulation (DBS) Retrospective Outcomes Study Recruiting
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04706234 on ClinicalTrials.gov ↗ ← All trials in Spain